Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of planktonic pseudomonas aeruginosa exposed to tobramycin treatment

ABSTRACT: As a comparison to tobramycin-treated P. aeruginosa biofilms, we investigated the response of planktonic P. aeruginosa to tobramycin by microarray. Experiment Overall Design: We included 2 control (untreated) cultures and 2 tobramycin-treated cultures. We used mid-exponential phase cultures of P. aeruginosa PA14. Replicate cultures were incubated in the presence or absence of 5 Î¼g/mL tobramycin for 30 minutes at 37Â°C.

ORGANISM(S): Pseudomonas aeruginosa

SUBMITTER: George O'Toole

PROVIDER: E-GEOD-9991 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells.

Anderson Gregory G GG Moreau-Marquis Sophie S Stanton Bruce A BA O'Toole George A GA

Infection and immunity 20080122 4

P. aeruginosa forms biofilms in the lungs of individuals with cystic fibrosis (CF); however, there have been no effective model systems for studying biofilm formation in the CF lung. We have developed a tissue culture system for growth of P. aeruginosa biofilms on CF-derived human airway cells that promotes the formation of highly antibiotic-resistant microcolonies, which produce an extracellular polysaccharide matrix and require the known abiotic biofilm formation genes flgK and pilB. Treatment ...[more]

PMID: 18212077

Similar Datasets

Transcription profiling of Pseudomonas aeruginosa treated with tobramycin

Project description:This SuperSeries is composed of the following subset Series:; GSE9989: Tobramycin Treatment of P. aeruginosa Biofilms Grown on CFBE41o- Cells; GSE9991: Tobramycin Treatment of Planktonic Pseudomonas aeruginosa Experiment Overall Design: Refer to individual Series

2008-06-18 | E-GEOD-10030 | biostudies-arrayexpress

Transcription profiling of P. aeruginosa biofilms treated with tobramycin grown on CFBE41o- cells

Project description:We grew Pseudomonas aeruginosa biofilms on CFBE41o- human airway cells in culture, and we treated these biofilms with tobramycin. Microarray analysis was performed to gain an understanding of the global transcriptional changes that occur during antibiotic treatment. Experiment Overall Design: We compared three untreated control samples with three tobramycin-treated samples. Biofilms were grown on CFBE41o- cells in culture for 9 hours in MEM/0.4% arginine. Replicate samples were then incubated in the presence or absence of 500 Î¼g/mL tobramycin for 30 minutes.

2008-06-18 | E-GEOD-9989 | biostudies-arrayexpress

Kristen-PAO1-anaerobic lethal concentrations tobramycin

Project description:To see the effects of tobramycin on Pseudomonas aeruginosa under anaerboc lethal conditions. RNA was isolated from 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 and 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 after being treated with 20 ug/ml tobramycin for 30 minutes.

2011-01-20 | E-FPMI-24 | biostudies-arrayexpress

Kristen-PAO1 aerobic sub-inhibitory cond. tobramycin

Project description:To see the effect of sub-inhibitory concentrations of tobramycin on Pseudomonas aeruginosa grown under aerobic conditions. RNA was isolated form 4 biological repeats of P.aeruginosa grown to mid-log in cationic adjusted mueller hinton broth and 4 biological repeats of P.aeruginosa with the addition of 0.25ug/ml tobramycin in cationic adjusted mueller hinton broth. null

2011-03-30 | E-FPMI-23 | biostudies-arrayexpress

Kristen-PAO1 aerobic lethal concentrations of Tobramycin

Project description:To see the effect of lethal concentrations of tobramycin on Pseudomonas aeruginosa grown under aerobic conditions. RNA was isolated from 4 biological repeats of P.aeruginosa grown to mid-log in cationic adjusted mueller hinton broth containing 15mM KNO3 and 4 biological repeats of P.aeruginosa grown to mid-log in cationic adjusted mueller hinton broth containing 15mM KNO3 and treated with 2 ug/ml tobramycin for 30 minutes. null

2011-01-20 | E-FPMI-26 | biostudies-arrayexpress

Kristen-PAO1-anaerobic sub-lethal concentrations tobramycin

Project description:To see the effect of sub-lethal concentration of tobramcyin on PAO1 under anaerobic conditions. RNA was isolated from 5 biological repeats of PAO1 grown to mid-log phase in cationic adjusted mueller hinton broth containing 15mM KNO3 and 5 biological repeats of PAO1 grown to mid-log phase in cationic adjusted mueller hinton broth containing 15mM KNO3 and then treated for 30 minutes with 2 ug/ml tobramycin. All flasks were sealed to create anaerobic conditions. null

2011-01-20 | E-FPMI-25 | biostudies-arrayexpress

Gene expression analysis of Pseudomonas aeruginosa wild type, delta-gbdR, and delta-plcHR deletion mutants

Project description:Pseudomonas aeruginosa is a virulent opportunistic pathogen responsible for high morbity in COPD, burns , implanted medical devices and cystic fibrosis. Pseudomonas aeruginosa is a problematic colonizer of the human lung. P. aeruginosa produces a phospholipase C (PlcH) that degrades choline-containing lipids such as phosphatidylcholine and sphingomylein that are found in lung surfactant and in host membranes. In this study, we analyzed gene expression in mutants defective in PlcH production (delta-plcH and delta-gbdR) and the wild type when growing in medium with lung surfactant. Pseudomonas aeruginosa was cultured in liquid cultures with aeration in a defined medium with Survanta, a lung surfactant replacement. Cultures were harvested during mid-exponential phase, and RNA was isolated for microarray analysis. The P. aeruginosa strain PAO1 wild type gene expression was compared to expression profiles from delta-gbdR and delta-plcHR deletion mutants, two mutants defective in PlcH production.

2013-01-01 | E-GEOD-41926 | biostudies-arrayexpress

Experimental evolution of Pseudomonas aeruginosa biofilms exposed to furanone C-30 with and without tobramycin

Project description:The aim of this study is to evaluate the evolutionary robustness of the quorum sensing inhibitor (QSI) furanone C-30 for the treatment of P. aeruginosa biofilm infections. We repeatedly exposed P. aeruginosa biofilms to furanone C-30 (with or without tobramycin) in the synthetic cystic fibrosis sputum medium (SCFM2) and characterized the genotype and phenotype of the evolved lineages. P. aeruginosa biofilms were grown in SCFM2 for 24 h after which the treatment in fresh SCFM2 was added to obtain a final concentration of 20 µg/ml tobramycin and 100 µg/ml furanone C-30. The negative control was treated with fresh SCFM2, including the same amount of DMSO (0.25%) as for the biofilms treated with C-30. After 24 h of static incubation at 37°C, biofilms were sonicated and vortexed in order to disintegrate the biofilm aggregates. After each cycle the number of CFU was determined and an aliquot of the culture was stored at -80°C in Microbank vials to allow further tests on the evolved strains. A sample from the treated biofilm was used to prepare a new overnight culture, in order to start a new cycle. For each treatment three independent lineages were established, that were each exposed for 16 cycles. Whole-genome sequencing was performed on the wild type P. aeruginosa PAO1 and on the exposed lineages after 5, 10 and 16 cycles.

2021-03-05 | E-MTAB-10124 | biostudies-arrayexpress

Transcription profiling of Pseudomonas aeruginosa PAO1-psrA::Tn vs. PAO1 in LB

Project description:b-Oxidative enzymes for fatty acid degradation (Fad) of long-chain fatty acid (LCFA), a component of lung surfactant phosphatidylcholine, are induced in vivo during lung infection in cystic fibrosis patients, which could contribute to nutrient acquisition and pathogenesis of Pseudomonas aeruginosa. In addition, fatty acid biosynthesis (Fab) is essential for the syntheses of two virulence controlling acylated-homoserine-lactone molecules in this organism. We mapped the promoter regions of the fadBA5-operon (PA3014 and PA3013) and a fadE homologue (PA2815) involved in Fad and the fabAB-operon involved in Fab. Focusing on the transposon mutagenesis of strain PAO1 carrying the PfadBA5-lacZ fusion, we identified a regulator for the fadBA5-operon to be PsrA (PA3006). Transcriptome analysis of the DpsrA mutant indicates its importance in regulating b-oxidative enzymes, which confirms a previous proteomic study. We further showed that induction of the fadBA-operon responds to LCFA signals, and this induction requires the presence of PsrA, suggesting that PsrA binds to LCFA to derepress fadBA5. Electrophoresis mobility shift assay indicate specific binding of PsrA to the fadBA5-promoter region. This binding is disrupted by specific LCFA (C18:1D9, C16:0, and to a lesser extent C14:0), but not by the first intermediate of b-oxidation, acyl-CoA. We proposed that PsrA is a Fad-regulator that binds and responds to LCFA signals in Pseudomonas aeruginosa. Experiment Overall Design: PAO1 and PAO1-psrA::Tn cultures grown in LB and cells were harvested at mid-log phase. Total RNA was isolated from both samples, and used for cDNA synthesis. And then, the cDNA for both samples were fragmented and labeled. The cDNA of PAO1 was used for 2 GeneChips, and PAO1-psrA::Tn cDNA was used for three GeneChips.

2008-04-07 | E-GEOD-8083 | biostudies-arrayexpress

Environment-driven changes of mRNA and protein levels in Pseudomonas aeruginosa

Project description:LFQ proteome datasets of Pseudomonas aeruginosa type strain PA14 cultured at different enviromental conditions: Exponential-, transition- and stationary(12 h and 24 h)growth phases. Biofilm (24 h and 48 h), low osmolarity conditions (control = exponential phase), iron starvation and respective control, Sub-MIC ciproflox treatment and respective control.

2018-11-20 | PXD010200 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data